Working... Menu

Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03195192
Recruitment Status : Recruiting
First Posted : June 22, 2017
Last Update Posted : March 4, 2019
Translational Drug Development
Information provided by (Responsible Party):
Side-Out Foundation

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 9, 2019
  Estimated Study Completion Date : June 9, 2019